Haruo Nishijima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haruo Nishijima has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Masahiko Tomiyama
63 shared publicationsChieko Suzuki
Department of Neurology Hirosaki University Graduate School of Medicine Hirosaki Japan
40 shared publicationsRie Haga
Department of Neurology, Aomori Prefectural Central Hospital, 2-1-1 Higashi-Tsukurimichi, Aomori, 030-8551, Japan
31 shared publicationsMasayuki Baba
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan
29 shared publicationsAkira Arai
Department of Neurology, Aomori Prefectural Central Hospital, 2-1-1 Higashi-Tsukurimichi, Aomori 030-8551, Japan
28 shared publications- Tomoya Kon
Department of Neurology, Hirosaki University Graduate School of Medicine , Hirosaki
28 shared publications
Latest Publications
- 29 October 2026
- Published by Elsevier in The American Journal of Medicine
Mesenteric phlebosclerosis associated with herbal medicine
- 29 October 2026
- Published by Elsevier in The American Journal of Medicine
Mesenteric phlebosclerosis associated with herbal medicine
- Open Access
- 9 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Resolution of Visual Hallucinations in Parkinson’s Disease After Right Occipitoparietal Subcortical Hemorrhage: A Case Report
Visual hallucinations are common non-motor symptoms of Parkinson’s disease (PD) that substantially impair quality of life, particularly in advanced stages. However, the neural substrates underlying visual hallucinations in PD remain incompletely understood. Here, we report a rare case of a 72-year-old right-handed man with PD whose visual hallucinations completely resolved after a right occipitoparietal subcortical hemorrhage. He developed PD at 58 years of age and later experienced wearing-off, dyskinesia, cognitive decline, visual hallucinations, and a false sense of presence. At 72 years of age, he presented with headache, nausea, and worsening gait. Neuroimaging demonstrated a right occipitoparietal subcortical hemorrhage. After the hemorrhagic event, visual hallucinations disappeared completely, whereas the false sense of presence persisted. Follow-up MRI three months later showed a residual lesion confined to the right precuneus. The patient remained free of visual hallucinations for several months. This case suggests that the right occipitoparietal region, particularly the precuneus, may play an important role in the generation of visual hallucinations in PD, while persistence of non-visual hallucinations supports partially distinct neural substrates. To our knowledge, this is the first reported case of PD in which visual hallucinations resolved following a hemorrhagic event, providing insight into the neuroanatomical mechanisms of hallucinations in PD.
- 9 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Open AccessResolution of Visual Hallucinations in Parkinson’s Disease After Right Occipitoparietal Subcortical Hemorrhage: A Case Report
Visual hallucinations are common non-motor symptoms of Parkinson’s disease (PD) that substantially impair quality of life, particularly in advanced stages. However, the neural substrates underlying visual hallucinations in PD remain incompletely understood. Here, we report a rare case of a 72-year-old right-handed man with PD whose visual hallucinations completely resolved after a right occipitoparietal subcortical hemorrhage. He developed PD at 58 years of age and later experienced wearing-off, dyskinesia, cognitive decline, visual hallucinations, and a false sense of presence. At 72 years of age, he presented with headache, nausea, and worsening gait. Neuroimaging demonstrated a right occipitoparietal subcortical hemorrhage. After the hemorrhagic event, visual hallucinations disappeared completely, whereas the false sense of presence persisted. Follow-up MRI three months later showed a residual lesion confined to the right precuneus. The patient remained free of visual hallucinations for several months. This case suggests that the right occipitoparietal region, particularly the precuneus, may play an important role in the generation of visual hallucinations in PD, while persistence of non-visual hallucinations supports partially distinct neural substrates. To our knowledge, this is the first reported case of PD in which visual hallucinations resolved following a hemorrhagic event, providing insight into the neuroanatomical mechanisms of hallucinations in PD.
- 28 November 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1336-1337
Phenomenology Video: A Rare Causee of Dyspnea—Respiratory Laryngeal Dystonia
- 28 November 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1336-1337
Phenomenology Video: A Rare Causee of Dyspnea—Respiratory Laryngeal Dystonia
- Open Access
- 2 October 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (1) , 234-240
Morphological Changes in Direct Pathway Striatal Neurons in a Rat Model of Tardive Dyskinesia
Background: Tardive dyskinesia (TD) and drug‐induced parkinsonism (DIP) arise from prolonged dopamine antagonist use. Although D2 receptor hypersensitivity in the indirect pathway is a proposed mechanism, the role of the direct pathway remains unclear. Objectives: To investigate morphological changes in the direct pathway striatal neurons' axon terminals in a rat model of haloperidol‐induced TD and DIP. Methods: Male Wistar rats received haloperidol decanoate or placebo over 6 months. Behavioral tests assessed TD‐ and DIP‐like symptoms. Axon terminals forming synapses on dendrites in the internal (GPi) and external (GPe) segments of the globus pallidus were analyzed using electron and immunoelectron microscopy. Results: Haloperidol‐treated rats exhibited both TD‐ and DIP‐like behaviors. Vesicular gamma‐aminobutyric acid (GABA) transporter (VGAT)‐positive terminals were selectively enlarged in the GPi, and substance P colocalization indicated a direct pathway origin. Conclusions: Structural alterations in direct pathway nerve terminals may contribute to TD, challenging conventional models that focus solely on the indirect pathway. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 2 October 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (1) , 234-240
Open AccessMorphological Changes in Direct Pathway Striatal Neurons in a Rat Model of Tardive Dyskinesia
Background: Tardive dyskinesia (TD) and drug‐induced parkinsonism (DIP) arise from prolonged dopamine antagonist use. Although D2 receptor hypersensitivity in the indirect pathway is a proposed mechanism, the role of the direct pathway remains unclear. Objectives: To investigate morphological changes in the direct pathway striatal neurons' axon terminals in a rat model of haloperidol‐induced TD and DIP. Methods: Male Wistar rats received haloperidol decanoate or placebo over 6 months. Behavioral tests assessed TD‐ and DIP‐like symptoms. Axon terminals forming synapses on dendrites in the internal (GPi) and external (GPe) segments of the globus pallidus were analyzed using electron and immunoelectron microscopy. Results: Haloperidol‐treated rats exhibited both TD‐ and DIP‐like behaviors. Vesicular gamma‐aminobutyric acid (GABA) transporter (VGAT)‐positive terminals were selectively enlarged in the GPi, and substance P colocalization indicated a direct pathway origin. Conclusions: Structural alterations in direct pathway nerve terminals may contribute to TD, challenging conventional models that focus solely on the indirect pathway. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 28 August 2025
- Published by Elsevier in Neuroscience Research
- Vol. 219, 104953
Morphologic changes in striatonigral neurons in a rat model of levodopa-induced dyskinesia
- 28 August 2025
- Published by Elsevier in Neuroscience Research
- Vol. 219, 104953
Open AccessMorphologic changes in striatonigral neurons in a rat model of levodopa-induced dyskinesia
- 17 April 2025
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 13 (4) , 279-281
Progressive Respiratory Failure in an Autopsy Case of Amyotrophic Lateral Sclerosis With Cardiac and Pulmonary Amyloidosis
A 76‐year‐old woman died of progressive respiratory failure 10 months after amyotrophic lateral sclerosis (ALS) onset. At autopsy, a neuropathological diagnosis of ALS was made. Only mild neurogenic changes appeared in the diaphragm. Transthyretin amyloid deposits were observed in the heart and lungs and diffusely located in the alveolar parenchyma, indicating diffuse alveolar‐septal pulmonary amyloidosis, which could impair gas exchange. Pulmonary amyloidosis may contribute to respiratory failure, potentially acting synergistically with respiratory muscle paralysis due to ALS and cardiac failure caused by cardiac amyloidosis.
- 17 April 2025
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 13 (4) , 279-281
Progressive Respiratory Failure in an Autopsy Case of Amyotrophic Lateral Sclerosis With Cardiac and Pulmonary Amyloidosis
A 76‐year‐old woman died of progressive respiratory failure 10 months after amyotrophic lateral sclerosis (ALS) onset. At autopsy, a neuropathological diagnosis of ALS was made. Only mild neurogenic changes appeared in the diaphragm. Transthyretin amyloid deposits were observed in the heart and lungs and diffusely located in the alveolar parenchyma, indicating diffuse alveolar‐septal pulmonary amyloidosis, which could impair gas exchange. Pulmonary amyloidosis may contribute to respiratory failure, potentially acting synergistically with respiratory muscle paralysis due to ALS and cardiac failure caused by cardiac amyloidosis.
- Open Access
- 4 March 2025
- Published by Springer Nature in Research Square
Deep vein thrombosis among patients with mild cognitive decline
The prevalence of deep vein thrombosis (DVT) is high in patients with severe major neurocognitive disorders and motor deficits. However, it is unknown whether patients with mild cognitive decline without major motor deficits have an increased risk for DVT. Recently, Nakanishi et al. proposed the Himi score to evaluate DVT risk in frail elderly individuals. The score accounts for the independence level in daily life among patients with dementia, graded as I/II, III, IV and M, as an assessment item. In the present study, we investigated DVT prevalence among patients with mild cognitive decline. Participants were recruited from the patients who visited our outpatient clinic between August 2022 and February 2023. To be eligible for enrollment, patients were required to be diagnosed with mild cognitive impairment or early-stage major neurocognitive disorder and able to walk independently. Individuals were excluded if they had an active malignancy, had a bed rest time of more than 24 h owing to an external injury within 3 months before the study, received general anesthesia, or had undergone central venous access catheter insertion within 3 months before the study. Overall, written informed consent was obtained from 22 patients. Clinical data, including the Mini-Mental State Examination and Alzheimer’s Disease Assessment Scale-Cognitive scores, were collected. Physical examinations were performed to evaluate the following symptoms in the lower extremities: pain, edema, erythema, varicose veins, and Homan’s sign. We calculated the Wells score and Padua Prediction score, which are well-established for evaluating DVT risk. We also calculated the Himi score. Whole-leg vein ultrasonography was performed to detect DVT in 12 patients with leg symptoms or elevated blood d-dimer levels. DVT was detected in two of the 22 participants (9%). Although the DVT prevalence in the general population is unknown, our pilot study results may reflect increased prevalence of DVT in patients with mild cognitive decline without major motor impairment. Neither patient with DVT had a major risk for DVT according to the Wells and Padua Prediction scores. In contrast, two patients had high Himi scores, suggesting that low activities of daily living owing to cognitive decline are associated with DVT. Our data suggest that the Himi score is useful for detecting potential DVT risks in elderly individuals without apparent motor deficits or other major risk factors.
- 4 March 2025
- Published by Springer Nature in Research Square
Open AccessDeep vein thrombosis among patients with mild cognitive decline
The prevalence of deep vein thrombosis (DVT) is high in patients with severe major neurocognitive disorders and motor deficits. However, it is unknown whether patients with mild cognitive decline without major motor deficits have an increased risk for DVT. Recently, Nakanishi et al. proposed the Himi score to evaluate DVT risk in frail elderly individuals. The score accounts for the independence level in daily life among patients with dementia, graded as I/II, III, IV and M, as an assessment item. In the present study, we investigated DVT prevalence among patients with mild cognitive decline. Participants were recruited from the patients who visited our outpatient clinic between August 2022 and February 2023. To be eligible for enrollment, patients were required to be diagnosed with mild cognitive impairment or early-stage major neurocognitive disorder and able to walk independently. Individuals were excluded if they had an active malignancy, had a bed rest time of more than 24 h owing to an external injury within 3 months before the study, received general anesthesia, or had undergone central venous access catheter insertion within 3 months before the study. Overall, written informed consent was obtained from 22 patients. Clinical data, including the Mini-Mental State Examination and Alzheimer’s Disease Assessment Scale-Cognitive scores, were collected. Physical examinations were performed to evaluate the following symptoms in the lower extremities: pain, edema, erythema, varicose veins, and Homan’s sign. We calculated the Wells score and Padua Prediction score, which are well-established for evaluating DVT risk. We also calculated the Himi score. Whole-leg vein ultrasonography was performed to detect DVT in 12 patients with leg symptoms or elevated blood d-dimer levels. DVT was detected in two of the 22 participants (9%). Although the DVT prevalence in the general population is unknown, our pilot study results may reflect increased prevalence of DVT in patients with mild cognitive decline without major motor impairment. Neither patient with DVT had a major risk for DVT according to the Wells and Padua Prediction scores. In contrast, two patients had high Himi scores, suggesting that low activities of daily living owing to cognitive decline are associated with DVT. Our data suggest that the Himi score is useful for detecting potential DVT risks in elderly individuals without apparent motor deficits or other major risk factors.
- Open Access
- 9 January 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (1) , e12524
Co‐Expression of Tardive Dyskinesia and Drug‐Induced Parkinsonism in Rats Chronically Treated With Haloperidol
Aim: We aimed to create a rat model of drug‐induced parkinsonism and tardive dyskinesia by chronic administration of haloperidol and examine the expression of direct and indirect pathway markers in the striatum of the model rats. Methods: We treated 21 rats, 14 with haloperidol decanoate and 7 with placebo. The number of vacuous chewing movements per 2 min was counted, and haloperidol‐treated rats were classified into two groups: mild and severe tardive dyskinesia. Other behavioral analyses were also conducted. After a 6‐month treatment period, rat brains were removed, and protein expression was evaluated by Western blotting. Results: All haloperidol‐treated rats exhibited vacuous chewing movements. The frequency of exploratory behavior and rotarod test performance was lower in the mild and severe tardive dyskinesia groups. The number of vacuous chewing movements and frequency of exploratory behavior were positively correlated in haloperidol‐treated rats. The expression of dynorphin, a direct pathway marker, decreased in the severe tardive dyskinesia group. The expression of enkephalin, an indirect pathway marker, decreased both in the mild and severe tardive dyskinesia groups. The expression of dopamine D1 and D2 receptors also decreased with haloperidol treatment. Conclusion: Both direct and indirect pathways are involved in haloperidol‐induced movement disorders.
- 9 January 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (1) , e12524
Open AccessCo‐Expression of Tardive Dyskinesia and Drug‐Induced Parkinsonism in Rats Chronically Treated With Haloperidol
Aim: We aimed to create a rat model of drug‐induced parkinsonism and tardive dyskinesia by chronic administration of haloperidol and examine the expression of direct and indirect pathway markers in the striatum of the model rats. Methods: We treated 21 rats, 14 with haloperidol decanoate and 7 with placebo. The number of vacuous chewing movements per 2 min was counted, and haloperidol‐treated rats were classified into two groups: mild and severe tardive dyskinesia. Other behavioral analyses were also conducted. After a 6‐month treatment period, rat brains were removed, and protein expression was evaluated by Western blotting. Results: All haloperidol‐treated rats exhibited vacuous chewing movements. The frequency of exploratory behavior and rotarod test performance was lower in the mild and severe tardive dyskinesia groups. The number of vacuous chewing movements and frequency of exploratory behavior were positively correlated in haloperidol‐treated rats. The expression of dynorphin, a direct pathway marker, decreased in the severe tardive dyskinesia group. The expression of enkephalin, an indirect pathway marker, decreased both in the mild and severe tardive dyskinesia groups. The expression of dopamine D1 and D2 receptors also decreased with haloperidol treatment. Conclusion: Both direct and indirect pathways are involved in haloperidol‐induced movement disorders.
- Open Access
- 23 July 2024
- Published by Springer Nature in Cureus
- Vol. 16 (7) , e65223
Withdrawal Dyskinesia Associated With Aripiprazole in a Child: A Case Report
Atypical antipsychotics are considered to be better tolerated than typical antipsychotics; however, the risk of drug-induced movement disorders needs to be considered. Aripiprazole, a dopamine partial agonist, is one of the most frequently used atypical antipsychotics in children. In this report, we describe withdrawal dyskinesia after aripiprazole discontinuation in a child with autism spectrum disorder. The patient presented with oral dyskinesia after discontinuation of aripiprazole when he was 13 years old. Dyskinetic movements disappeared after reinitiation of aripiprazole. He developed oral dyskinesia again after a reduction of the aripiprazole dose when he was 14 years old. Dyskinesia gradually disappeared within a few months. Withdrawal dyskinesia associated with aripiprazole has been rarely reported in children. Moreover, there is no large study on the prevalence of dyskinesia associated with aripiprazole discontinuation either in adults or in children. However, relevant cases might be unreported, pretermitted, or regarded as akathisia or symptoms of attention-deficit hyperactivity disorder. The prevalence of withdrawal dyskinesia associated with aripiprazole, especially in children, may be more frequent than thought. Withdrawal dyskinesia is selflimited; however, such dyskinetic movements in children potentially result in irreversible effects that damage the quality of life. As such, physicians should be mindful when changing, reducing, or discontinuing antipsychotics in children.
- 23 July 2024
- Published by Springer Nature in Cureus
- Vol. 16 (7) , e65223
Open AccessWithdrawal Dyskinesia Associated With Aripiprazole in a Child: A Case Report
Atypical antipsychotics are considered to be better tolerated than typical antipsychotics; however, the risk of drug-induced movement disorders needs to be considered. Aripiprazole, a dopamine partial agonist, is one of the most frequently used atypical antipsychotics in children. In this report, we describe withdrawal dyskinesia after aripiprazole discontinuation in a child with autism spectrum disorder. The patient presented with oral dyskinesia after discontinuation of aripiprazole when he was 13 years old. Dyskinetic movements disappeared after reinitiation of aripiprazole. He developed oral dyskinesia again after a reduction of the aripiprazole dose when he was 14 years old. Dyskinesia gradually disappeared within a few months. Withdrawal dyskinesia associated with aripiprazole has been rarely reported in children. Moreover, there is no large study on the prevalence of dyskinesia associated with aripiprazole discontinuation either in adults or in children. However, relevant cases might be unreported, pretermitted, or regarded as akathisia or symptoms of attention-deficit hyperactivity disorder. The prevalence of withdrawal dyskinesia associated with aripiprazole, especially in children, may be more frequent than thought. Withdrawal dyskinesia is selflimited; however, such dyskinetic movements in children potentially result in irreversible effects that damage the quality of life. As such, physicians should be mindful when changing, reducing, or discontinuing antipsychotics in children.
- Open Access
- 15 May 2024
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 18, 1400001
Case report: Early-onset Parkinson’s disease with lower limb spasticity in a new DJ-1/PARK7 patient
Rare autosomal recessive variants in DJ-1, a causative gene for early-onset Parkinson’s disease, have been associated with a variety of clinical syndromes in a limited number of patients. Here, we report a case of a novel DJ-1 variant in a 39-year-old man with a 4-year history of parkinsonism, cognitive dysfunction, and lower limb spasticity. He was diagnosed with Parkinson’s disease. Genetic testing of the patient revealed compound heterozygous variants in the DJ-1 gene (exon 6 deletion + c.242dup), of which exon 6 deletion was a novel variant. We conclude that variants in DJ-1 should be considered possible causes of early-onset parkinsonism with spasticity and cognitive impairment, as in this case.
- 15 May 2024
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 18, 1400001
Open AccessCase report: Early-onset Parkinson’s disease with lower limb spasticity in a new DJ-1/PARK7 patient
Rare autosomal recessive variants in DJ-1, a causative gene for early-onset Parkinson’s disease, have been associated with a variety of clinical syndromes in a limited number of patients. Here, we report a case of a novel DJ-1 variant in a 39-year-old man with a 4-year history of parkinsonism, cognitive dysfunction, and lower limb spasticity. He was diagnosed with Parkinson’s disease. Genetic testing of the patient revealed compound heterozygous variants in the DJ-1 gene (exon 6 deletion + c.242dup), of which exon 6 deletion was a novel variant. We conclude that variants in DJ-1 should be considered possible causes of early-onset parkinsonism with spasticity and cognitive impairment, as in this case.